Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 2, Issue 4, Pages 382-387Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S1471-4892(02)00183-2
Keywords
-
Categories
Ask authors/readers for more resources
Clinical trials of selective small-molecule, inhibitors of epidermal growth factor receptor tyrosine kinase activity have shown that these targeted inhibitors of proliferative signal transduction provide well-tolerated antitumour activity in patients. Preclinical pharmacology studies illustrate the potential use of these new cancer therapeutics in combination with chemotherapy, radiotherapy and hormone therapy, and in chemoprevention, in a spectrum of solid human tumours.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available